Novartis/QLT To File Visudyne Occult CNV sNDA; Classic CNV "Approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis Ophthalmics and QLT expect to file an sNDA in July for use of Visudyne (verteporfin) in the treatment of "wet" age-related macular degeneration in patients with occult subfoveal choroidal neovascularization (CNV).